CLAIMS

1. The use of benzydamine or the physiologically acceptable acid addition salts thereof in the manufacture of a medicament for the treatment of an inflammatory disease caused by the expression of cytokine subunit p40.
2. The use according to claim 1, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
3. The use according to claim 1, wherein said medicament is formulated for systemic or topical administration.
4. The use according to claim 3, wherein said medicament for systemic administration comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.
5. The use according to claim 3, wherein said medicament for topical administration comprises an amount of from 1% to 20%, more preferably from 1% to 10%, by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the medicament.
6. A method for the treatment of an inflammatory disease caused by the expression of cytokine subunit p40 comprising the administration in a patient in need thereof of a therapeutically effective amount of benzydamine or the physiologically acceptable acid addition salts thereof.
7. The method according to claim 6, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
8. The method according to claim 6, wherein said administration is provided at a daily dosage of from 50 mg/kg to 0.1 mg/kg of

benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

9. The method according to claim 8, wherein said administration is provided by systemic or topical route.

10. The method according to claim 9, wherein said systemic administration is provided at a daily dosage of from 5 mg/kg to 0.1 mg/kg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

11. The method according to claim 9, wherein said topical administration is provided at a daily dosage of from 50 mg/kg to 1 mg/kg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

12. A pharmaceutical composition for the treatment of an inflammatory disease caused by the expression of cytokine subunit p40 by systemic or topical administration, wherein said pharmaceutical composition comprises benzydamine or the physiologically acceptable acid addition salts thereof.

13. The pharmaceutical composition for systemic administration according to claim 12, wherein said pharmaceutical composition comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

14. The pharmaceutical composition for topical administration according to claim 12, wherein said pharmaceutical composition comprises of from 1% to 20%, more preferably from 1% to 10%, by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the composition.

15. The pharmaceutical composition for topical administration according to any one of claims 12 to 14, wherein said

physiologically acceptable acid addition salt of benzydamine is obtained with a mineral or organic acid selected from the group comprising hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, ascorbic acid, benzoic acid, citric acid, fumaric acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-toluenesulfonic acid, benzensulfonic acid, succinic acid, tannic acid and tartaric acid.

CLAIMS

1. The use of benzydamine or the physiologically acceptable acid addition salts thereof in the manufacture of a medicament for the treatment of an inflammatory disease caused by the expression of cytokine subunit p40, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, psoriatic arthritis, and psoriasis.

2. The use according to claim 1, wherein said medicament is formulated for systemic or topical administration.

3. The use according to claim 2, wherein said medicament for systemic administration comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

4. The use according to claim 2, wherein said medicament for topical administration comprises an amount of from 1% to 20%, more preferably from 1% to 10%, by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the medicament.

5. The use according to claim 2, wherein said medicament is administrated at a daily dosage of from 50 mg/kg to 0.1 mg/kg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

6. The use according to claim 2, wherein said medicament for systemic administration is administrated at a daily dosage of from 5 mg/kg to 0.1 mg/kg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

7. The use according to claim 2, wherein said medicament for topical administration is administrated at a daily dosage of from 50 mg/kg to 1 mg/kg of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

8. A pharmaceutical composition for the treatment of an inflammatory disease caused by the expression of cytokine subunit p40 by systemic or topical administration, wherein said inflammatory disease is selected from the group consisting of Crohn's disease, psoriatic arthritis, and psoriasis wherein said pharmaceutical composition comprises benzydamine or the physiologically acceptable acid addition salts thereof.

9. The pharmaceutical composition for systemic administration according to claim 8, wherein said pharmaceutical composition comprises an amount of from 1 mg to 100 mg, more preferably from 5 mg to 50 mg, of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base.

10. The pharmaceutical composition for topical administration according to claim 8, wherein said pharmaceutical composition comprises of from 1% to 20%, more preferably from 1% to 10%, by weight of benzydamine, or the physiologically acceptable acid addition salts thereof, expressed as free base, based on the total weight of the composition.